|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events.
|
30731283 |
2019 |
|
rs738409
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population.
|
29271184 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Because PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants are known to confer susceptibility to NAFLD, we assessed the influence of MBOAT7 rs641738 on hepatic steatosis, and serum levels of CK-18 fragment (a biomarker of hepatocellular injury and apoptosis for NAFLD) after adjusting the effects of PNPLA3, GCKR and TM6SF2 polymorphisms.
|
29314568 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Notably, the I148M PNPLA3 variant has been identified as the major common genetic determinant of NAFLD.
|
29122391 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In addition, PNPLA3 rs738409 may be more relevant to the progression of non-obese NAFLD when compared to obese NAFLD.
|
29609501 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Among individual variants, rs1260326 in GCKR and rs641738 in MBOAT7 (recessive), rs58542926 in TM6SF2 and rs738409 in PNPLA3 (dominant) emerged as associated to NAFLD, with PNPLA3 rs738409 being the strongest predictor (OR 3.12, 95% CI, 1.8-5.5, P < 0.001).
|
29487372 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Therefore, PNPLA3 rs738409 underlies the response to a variety of treatments, which warrants a personalized, precise medicine in NAFLD on the basis of genotype stratification.
|
30148144 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
As variants in PNPLA3 (I148M) and TM6SF2 (E167K) are associated with nonalcoholic fatty liver disease, we assessed these variants in type 2 diabetes (T2D) patients randomized to receive BIL (n=1822) or GL (n=1270) in three phase 3 trials.
|
29160303 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The risk alleles showed different metabolic effects: PNPLA3 rs738409-G, the strongest genetic NAFLD risk factor, did not associate with metabolic changes.
|
29648650 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
PNPLA3 I148M polymorphism can significantly affect histologically proven NAFLD at 1 year post-LT.
|
28718984 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Patatine-like phosphatas in domain 3 (PNPLA3; adiponutrin; SNP rs738409 C/G, M148I) shows anabolic and catabolic activities on lipid metabolism and significant association to fatty liver content; however, I148M demographics and ethnics, as its role with NAFLD have not been fully elucidated.
|
29055919 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The rs738409 single nucleotide polymorphism (SNP) in patatin-like phospholipase domain-containing protein 3 gene and the rs58542926 SNP in transmembrane 6 superfamily member 2 gene have been robustly associated with NAFLD and with its progression, but promising results have been obtained with many other SNPs.
|
30487694 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent major genetic risk factors for progressive liver injury in nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and chronic viral hepatitis.
|
30161167 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
PNPLA3 I148M was associated with a stepwise increase in liver fat content of up to 28% in MM vs. II-homozygotes (P-trend = 0.0001) and with ORs of 2.03 (1.52-2.70) for NAFLD (P = 3×10-7), 3.28 (2.37-4.54) for cirrhosis (P = 4×10-12), and 0.95 (0.86-1.04) for IHD (P = 0.46).
|
29228164 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Our aim was to investigate: (a) associations between NASH and BMD values and (b) associations between PNPLA3 I148M genotypes and BMD, in children with histologically proven non-alcoholic fatty liver disease (NAFLD).
|
30176114 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
As one of the genetic factors, PNPLA3 rs738409 (I148M) is important to associate with pathogenesis of NAFLD.
|
28497593 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
|
30032630 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Our study aimed to investigate the feasibility of a new index comprehensive index (CI), consisting of 6 serum biomarkers and anthropometric parameters through multivariate logistic regression analysis, to the earlier detection of NAFLD, and the diagnostic value of 5 SNPs (S1: rs2854116 of apolipoprotein C3 [APOC3], S2: rs4149267 of ATP-binding cassette transporter [ABCA1], S3: rs13702 of lipoprotein lipase [LPL], S4: rs738409 of protein 3 [patatin-like phospholipase domain containing protein 3 (PNPLA3)], S5: rs780094 of glucokinase regulatory protein gene [GCKR]) for NAFLD were also explored.
|
29595690 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The rs738409 and rs58542926 variants, but not rs641738, were associated not only with non-alcoholic steatohepatitis (NASH) (odds ratio [OR], 2.00; 95% confidence interval [CI], 1.46-2.73 and OR, 1.91; 95% CI, 1.04-3.51) but also with significant fibrosis (≥ F2) (OR, 1.53; 95% CI, 1.11-2.11 and OR, 1.88; 95% CI, 1.02-3.46) in NAFLD, even after adjustment for metabolic risk factors.
|
29193269 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We designed silymarin-loaded lipid polymer hybrid nanoparticles containing chitosan (CS-LPNs) to improve silymarin bioavailability and evaluated their lipid-lowering effect in adiponutrin/patatin-like phospholipase-3 I148M transgenic mice, an NAFLD model.
|
30176941 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The rs738409 c.444C > G (p.I148M) polymorphism in PNPLA3 is a major factor predisposing to non-alcoholic fatty liver disease.
|
29396131 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In non-obese NAFLD patients, the frequency of the PNPLA3 p.I148M allele (74.6%), but not of the TM6SF2 or MBOAT7 polymorphisms, was significantly (P < 0.05) higher as compared to the other patients in the NAFLD CSG cohort (54.9%) or controls (40.2%).
|
29483677 |
2018 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The genetic variation in Patatin-like phospholipase domain-containing protein 3 (PNPLA3), which is also called adiponutrin (ADPN), in residue 148 (I148M, rs738409) has been associated with NAFLD.
|
27514759 |
2017 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
A genetic variant of patatin-like phospholipase domain-containing 3 (PNPLA3-I14</span>8M) is the most prominent heritable factor associated with NAFLD.
|
29286303 |
2017 |
|
rs738409
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We determined the risk factors for HCC, including the PNPLA3 rs738409 polymorphism, in Japanese patients with biopsy-proven NAFLD.
|
27862719 |
2017 |